← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
92%Confidence
0Views
FDASource
2026-04-15Date

Summary

Redness relief eye drops from K.C. Pharmaceuticals with sterility issues affect industrial and pharmacy distribution channels. This demonstrates quality failures across the company's entire eye drop product line.

Actionable: Immediately halt distribution of all K.C. Pharmaceuticals eye drops until sterility assurance is verified.

AI Confidence: 92%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productSterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles; a) Industrial Eye Relief, Distributed by:

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now